We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Ahead of McKesson (MCK) Q2 Earnings: Get Ready With Wall Street Estimates for Key Metrics
Read MoreHide Full Article
In its upcoming report, McKesson (MCK - Free Report) is predicted by Wall Street analysts to post quarterly earnings of $8.92 per share, reflecting an increase of 26.2% compared to the same period last year. Revenues are forecasted to be $104.66 billion, representing a year-over-year increase of 11.8%.
Over the past 30 days, the consensus EPS estimate for the quarter has remained unchanged. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.
Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically rely on consensus earnings and revenue estimates to gauge how the business may have fared during the quarter, examining analysts' projections for some of the company's key metrics often helps gain a deeper insight.
Bearing this in mind, let's now explore the average estimates of specific McKesson metrics that are commonly monitored and projected by Wall Street analysts.
Analysts predict that the 'Revenue- Prescription Technology Solutions' will reach $1.39 billion. The estimate indicates a change of +9.7% from the prior-year quarter.
It is projected by analysts that the 'Revenue- Medical-Surgical Solutions' will reach $3.02 billion. The estimate indicates a change of +2.6% from the prior-year quarter.
Analysts expect 'Adjusted Operating Profit- Medical-Surgical Solutions' to come in at $246.33 million. The estimate compares to the year-ago value of $243.00 million.
The consensus estimate for 'Adjusted Operating Profit- Prescription Technology Solutions' stands at $245.96 million. The estimate compares to the year-ago value of $218.00 million.
Over the past month, shares of McKesson have returned +8.8% versus the Zacks S&P 500 composite's +2.1% change. Currently, MCK carries a Zacks Rank #1 (Strong Buy), suggesting that it may outperform. the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Ahead of McKesson (MCK) Q2 Earnings: Get Ready With Wall Street Estimates for Key Metrics
In its upcoming report, McKesson (MCK - Free Report) is predicted by Wall Street analysts to post quarterly earnings of $8.92 per share, reflecting an increase of 26.2% compared to the same period last year. Revenues are forecasted to be $104.66 billion, representing a year-over-year increase of 11.8%.
Over the past 30 days, the consensus EPS estimate for the quarter has remained unchanged. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.
Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically rely on consensus earnings and revenue estimates to gauge how the business may have fared during the quarter, examining analysts' projections for some of the company's key metrics often helps gain a deeper insight.
Bearing this in mind, let's now explore the average estimates of specific McKesson metrics that are commonly monitored and projected by Wall Street analysts.
Analysts predict that the 'Revenue- Prescription Technology Solutions' will reach $1.39 billion. The estimate indicates a change of +9.7% from the prior-year quarter.
It is projected by analysts that the 'Revenue- Medical-Surgical Solutions' will reach $3.02 billion. The estimate indicates a change of +2.6% from the prior-year quarter.
Analysts expect 'Adjusted Operating Profit- Medical-Surgical Solutions' to come in at $246.33 million. The estimate compares to the year-ago value of $243.00 million.
The consensus estimate for 'Adjusted Operating Profit- Prescription Technology Solutions' stands at $245.96 million. The estimate compares to the year-ago value of $218.00 million.
View all Key Company Metrics for McKesson here>>>Over the past month, shares of McKesson have returned +8.8% versus the Zacks S&P 500 composite's +2.1% change. Currently, MCK carries a Zacks Rank #1 (Strong Buy), suggesting that it may outperform. the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .